2025 iJURECON

Tuberculosis (TB) remains a global health threat, with high infection rates, particularly in developing countries. The Directly Observed Therapy, Short-course (DOTS) treatment, while effective, requires patients to take their medication daily in the presence of a healthcare officer, which poses a significant challenge for patients who live far from treatment centers or have personal constraints. This study aims to explore the experiences of Tuberculosis (TB) patients with DOTS treatment and to evaluate their acceptance of an innov ation called TB-VitaCure, a smart box for remote medication monitoring. Using a qualitative approach, semi-structured interviews were conducted with 10 TB patients and 10 nurses from a district health clinic. The study's findings indicate that patients face travel burdens, emotional stress, and the challenges of social stigma with daily DOTS treatment. Respondents were generally positive about the use of TB-VitaCure but emphasized the need for training in using the technology to ensure the system's effectiveness. This study supports the use of digital innovation in TB treatment to improve treatment adherence and reduce the burden on the healthcare system. The findings show that although DOTS is effective, its traditional implementation is physically and emotionally burdensome for patients. With TB-VitaCure, patients have the potential to receive treatment in a more comfortable environment, thereby increasing adherence rates. The TB-VitaCure innovation was well-received by TB patients as a more flexible and less burdensome alternative to DOTS treatment. The use of this technology needs to be supported by user education to overcome digital literacy constraints